Trials / Not Yet Recruiting
Not Yet RecruitingNCT07533708
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX3902 (a STEAP1xCD3xCD28 Trispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Advanced Solid Tumours
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX3902 | HLX3902 will be administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2026-05-25
- Primary completion
- 2027-06-29
- Completion
- 2028-05-24
- First posted
- 2026-04-16
- Last updated
- 2026-04-16
Source: ClinicalTrials.gov record NCT07533708. Inclusion in this directory is not an endorsement.